Comparative studies between GLP-1RAs and other antidiabetic agents, such as insulin, metformin, and sulfonylureas, show that GLP-1RAs are associated with reduced risks of hepatic decompensation, cirrhosis, HCC, and all-cause mortality [20-21]. Here, INS is linked to hepatocellular carcinoma.